Sao Paulo SP, Brazil

Jorge E Kalil-Filho


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:

goldMedal1 out of 832,718 
Other
 patents

Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Jorge E Kalil-Filho in the Treatment of Leishmaniasis.

Introduction

Jorge E Kalil-Filho is a notable inventor based in Sao Paulo, SP, Brazil. He has made significant contributions to the field of medicine, particularly in the treatment of cutaneous leishmaniasis. His innovative approach combines various compounds to create effective topical compositions for treating this parasitic infection.

Latest Patents

Kalil-Filho holds a patent for "Topical compositions for the treatment of cutaneous leishmaniasis." This invention relates to a composition that includes a combination of a (halogenoacetamido)benzoate, a flavonol, and a terpene. Specifically, it features a combination of ethyl 3-(2-chloroacetamido)benzoate, dihydroquercetin, and bisabolol. The composition is designed for topical application to treat both the parasitic infection and the skin inflammation caused by leishmaniasis.

Career Highlights

Throughout his career, Kalil-Filho has focused on developing innovative solutions for medical challenges. His work has been instrumental in advancing treatments for leishmaniasis, showcasing his commitment to improving patient outcomes. With 1 patent to his name, he continues to contribute to the field of medical research.

Collaborations

Kalil-Filho has collaborated with various professionals in his field, including his coworker, Esther Fellous. These collaborations have enhanced his research and development efforts, leading to more effective treatment options.

Conclusion

Jorge E Kalil-Filho's innovative work in developing topical compositions for the treatment of cutaneous leishmaniasis highlights his dedication to medical advancements. His contributions are vital in addressing the challenges posed by this disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…